Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
-
Published:2024-01
Issue:1
Volume:30
Page:249-256
-
ISSN:1078-8956
-
Container-title:Nature Medicine
-
language:en
-
Short-container-title:Nat Med
Author:
Jiang ZefeiORCID, Ouyang Quchang, Sun TaoORCID, Zhang Qingyuan, Teng Yuee, Cui Jiuwei, Wang HaiboORCID, Yin YongmeiORCID, Wang XiaojiaORCID, Zhou Xin, Wang Yongsheng, Sun Gang, Wang Jingfen, Zhang Lili, Yang Jin, Qian Jun, Yan MinORCID, Liu Xinlan, Yi Tienan, Cheng YingORCID, Li Man, Zang Aimin, Wang ShusenORCID, Wang Chuan, Wu Xinhong, Cheng Jing, Li Hui, Lin YingORCID, Geng Cuizhi, Gu Kangsheng, Xie Chunwei, Xiong Huihua, Wu Xiaohong, Yang Junlan, Li Qingshan, Chen YidingORCID, Li FanfanORCID, Zhang Anqin, Zhang Yongqiang, Wu Yudong, Nie JianyunORCID, Liu Qiang, Wang Kun, Mo Xueli, Chen Lilin, Pan YueyinORCID, Fu Peifen, Zhang Helong, Pang Danmei, Sheng Yuan, Han Yunwei, Wang Hongxia, Cang Shundong, Luo Xianming, Yu Wenbo, Deng Rong, Yang Chaoqiang, Keegan PatriciaORCID
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). 2. Waks, A. G. & Winer, E. P. Breast cancer treatment: a review. JAMA 321, 288–300 (2019). 3. O’Meara, T. A. & Tolaney, S. M. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget 12, 394–400 (2021). 4. Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598–2608 (2017). 5. Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl. J. Med. 379, 2108–2121 (2018).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|